190845-23-9Relevant academic research and scientific papers
Structure-activity relationships for acridine-substituted analogues of the mixed topoisomerase I/II inhibitor N-[2-(dimethylamino)ethyl] acridine- 4-carboxamide
Spicer, Julie A.,Gamage, Swarna A.,Atwell, Graham J.,Finlay, Graeme J.,Baguley, Bruce C.,Denny, William A.
, p. 1919 - 1929 (2007/10/03)
The mixed topoisomerase I/II inhibitor N-[2- (dimethylamino)ethyl]acridine-4-carboxamide (DACA) is currently in clinical trial as an anticancer drug. A series of acridine-substituted analogues were prepared, using a new synthetic route to substituted acri
A new synthesis of substituted acridine-4-carboxylic acids and the anticancer drug N-[2-dimethylamino)ethyl]acridine-4-carboxamide (DACA)
Gamage, Swarna A.,Spicer, Julie A.,Rewcastle, Gordon W.,Denny, William A.
, p. 699 - 702 (2007/10/03)
A new synthesis of substituted acridine-4-carboxylic acids 2 from methyl 2-[N-(2-carboxyphenyl)amino]benzoates (4) is reported, via NaBH4 reduction of the corresponding imidazolides (5), oxidation of the resulting alcohols 6 to aldehyde 7, and cyclisation of these with trifluoroacetic acid to the methyl acridine-4-carboxylates (8), followed by base hydrolysis. Direct amidation of 8a provides a new route to the clinical anticancer drug DACA (3) which avoids use of the irritant acid 2a.
